The 22nd Awaji International Forum on Infection and Immunity

○Nando Reza Pratama¹, Heny Arwati¹ (1. Universitas Airlangga (Indonesia))

○Alessandro Pardini^1,2,3, Dominik Alexander Rothen^1,2,3, Pascal Sigfried Krenger^1,2,3, Anne-Cathrine Sarah Vogt^1,2,3, Romano Josi^1,2,3, Monique Vogel^1,2, Manfred Kopf⁴, Martin Fabian Bachmann^1,2,5 (1. Department of BioMedical Research, University of Bern, Bern, (Switzerland), 2. Department of Rheumatology and Immunology, University Hospital Bern, Bern, (Switzerland), 3. Graduate School of Cellular and Biomedical Sciences, University of Bern, Bern, (Switzerland), 4. Institute of Molecular Health Sciences, ETH Zurich, Zurich (Switzerland), 5. Nuffield Department of Medicine, Centre for Cellular and Molecular Physiology (CCMP), The Jenner Institute, University of Oxford, Oxford, (UK))

Taro Shimizu^1,2,3, Hiroki Tanaka^3,4, Shintaro Shichinohe⁵, Toshiro Hirai^1,2,3,6, Tokiko Watanabe^3,5,7, Hidetaka Akita^3,4, ○Yasuo Yoshioka^1,2,3,6,7,8 (1. Vaccine Creation Group, Research Institute for Microbial Diseases, Osaka University (Japan), 2. OTRI, Osaka University (Japan), 3. CAMaD, Osaka University (Japan), 4. Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 5. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University (Japan), 6. Graduate School of Pharmaceutical Sciences, Osaka University (Japan), 7. CiDER, Osaka University (Japan), 8. The Research Foundation for Microbial Diseases of Osaka University (Japan))

○Shuntaro Shimizu^1,2,3,4, Tomoya Hayashi^1,2,3, Koji Sakamoto⁵, Naozumi Hashimoto⁶, Kouji Kobiyama^1,2,3, Hideo Negishi^1,2,3, Burcu Temizoz^1,2,3, Cevayir Coban^2,3,7, Ken Ishii^1,2,3 (1. Division of Vaccine Science, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan (Japan), 2. International Vaccine Design Center, IMSUT, Tokyo, Japan (Japan), 3. The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center (UTOPIA), The University of Tokyo, Japan (Japan), 4. Department of Chemistry, Chemical Engineering & Life Science, Yokohama National University, Kanagawa, Japan (Japan), 5. Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan (Japan), 6. Department of Respiratory Medicine, Fujita Health University, Nagoya, Japan (Japan), 7. Division of Malaria Immunology, Department of Microbiology and Immunology, IMSUT, Tokyo, Japan (Japan))

○Nantaporn Kaewaroon^1,2, Shintaro Shichinohe¹, Sara Yoshimoto¹, Tokiko Watanabe^1,3,4 (1. Department of Molecular Virology, Research Institute for Microbial Disease, Osaka University (Japan), 2. National Vaccine Institute (Thailand), 3. Center for Infectious Disease Education and Research (CiDER), Osaka University (Japan), 4. Center for Advanced Modalities and DDS (CAMaD), Osaka University, (Japan))